Accueil › Cancer de la prostate › Illinois › Decatur
Essais cliniques pour Cancer de la prostate à Decatur, IL
12 études pour Cancer de la prostate recherchent des participants dans et autour de Decatur (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Recrutement en coursPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Recrutement en coursPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Recrutement en coursPhase 2
- Cancer Care Specialists of Illinois - Decatur, Decatur
DESTINY-PANTUMOUR04
Recrutement en coursÉtude observationnelle
- Research Site, Decatur
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Recrutement en coursPhase 3
- Cancer Care Specialists of Illinois, Decatur
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Recrutement en coursPhase 3
- Cancer Care Specialists of Illinois, Decatur
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Recrutement en coursPhase 3
- Decatur Memorial Hospital, Decatur
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Recrutement en coursPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Recrutement en coursPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Vitamin D for Prostate Endocrine Therapy
Recrutement en coursPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Recrutement en coursPhase 3
- Decatur Memorial Hospital, Decatur
Essais pour Cancer de la prostate dans d'autres villes
- New York City, NY103 études
- Houston, TX76 études
- Los Angeles, CA61 études
- Boston, MA59 études
- St. Louis, MO46 études
- Chicago, IL45 études
- San Francisco, CA45 études
- Philadelphia, PA44 études
- Baltimore, MD43 études
- Nashville, TN42 études
- Seattle, WA42 études
- Washington, DC38 études
Autres études à Decatur
- Cancer du poumon non à petites cellules14 études
- Cancer du poumon10 études
- Cancer du sein8 études
- Cancer du rein (carcinome à cellules rénales)7 études
- Carcinome épidermoïde de la tête et du cou7 études
- Leucémie aiguë myéloïde7 études
- Cancer de la vessie6 études
- Cancer du pancréas6 études
- Cancer colorectal6 études
- Mélanome5 études
- Cancer de la bouche5 études
- Cancer de l'hypopharynx4 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.